Efficacy and safety of Novantron/etoposide vs FLANG regimen in relapsed/refractory acute leukemia

Efficacy and safety of Novantron/etoposide vs FLANG regimen in relapsed/refractory acute leukemia in patient older than 15 years old

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190618043939N1

Enrollment

Registered

2020-02-15

Start date

2019-06-22

Completion date

Unknown

Last updated

2020-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute leukemia. Lymphoid leukaemia

Interventions

Intervention 1: Intervention group: patient recieved FLANG regimen. Intervention 2: Intervention group: patient received Novantron/Etoposide regimen.

Eligibility

Sex/Gender

All

Age

15 Years to 60 Years

Inclusion criteria

Inclusion criteria: Patient older than 15 years old with established diagnosis of relapsed/refractory acute leukemia ECOG socre 0-2 2?serum creatinine Total billirubin <2 Serum ALT/AST <3 times the upper limit of normal

Exclusion criteria

Exclusion criteria: Pregnancy Breast-feeding

Design outcomes

Primary

Measure	Time frame
Progression free survival. Timepoint: 28 days after treatment. Method of measurement: Bone marrow biopsy/aspiration.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Maryam Mirpourian

Esfahan University of Medical Sciences

dr.m.mirpourian@gmail.com+98 31 3235 0210

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 12, 2026